October 16, 2020
Calvin Scott & Company Inc. is recalling diethylpropion tablets sent to physician consignees in five states. According to the October 14, 2020, US Food and Drug Administration (FDA) Enforcement Report, the tablets were repackaged without supporting stability studies.
The recall affects the following products:
- diethylpropion, 25-mg tablets (NDC 00527-1475-01), from lots CS19311 and CS19337 (Exp. 12/20); CS20018B, CS20019, CS20037, CS20075, CS20076, CS20112, and CS20169 (Exp. 8/21); CS20168 (Exp. 12/21); CS20199 (Exp. 5/22); and CS20243 (Exp. 7/22); and
- diethylpropion, 75-mg tablets (NDC 00527-1477-01), from lots CS19192, CS19226, and CS19263 (Exp. 10/20); CS19300 (Exp. 7/21); CS19338 (Exp. 8/21); CS20034 (Exp. 10/21); CS20077 (Exp. 1/22); and CS20165 and CS20241 (Exp. 4/22).
The recalled tablets were manufactured by Lannett Company and distributed by Calvin Scott & Company to 12 physician consignees in California, Idaho, Illinois, Oklahoma, and Rhode Island.
Calvin Scott & Company voluntarily initiated the recall September 16, 2020. On October 2, 2020, the FDA designated the recall Class II, signaling use of the medication could cause temporary or medically reversible adverse health consequences. A remote possibility of serious harm also exists.
Diethylpropion is a prescription stimulant that is used as an appetite suppressant to treat obesity.